Clinical Research Institute Inc of Minneapolis, Minneapolis, Minnesota 55402, USA.
Ann Allergy Asthma Immunol. 2010 May;104(5):440-9. doi: 10.1016/j.anai.2010.03.006.
Nighttime allergen exposures are a primary contributor to the development of allergic and asthmatic morbidities. Disease management guidelines recommend the use of environmental control measures to reduce these exposures, but clinically relevant reductions are difficult to achieve because most measures control only 1 allergen source among many in the bedroom environment.
To determine whether a novel localized approach to nighttime allergen avoidance provides effective exposure reductions and clinical benefits.
Thirty-five adults with perennial allergic rhinoconjunctivitis (dog, cat, or dust mite sensitivity) were randomized to receive PureZone, a combination therapy involving localized air filtration and pillow encasement, or placebo in a crossover trial with two 2-week treatment periods separated by a 1-week washout. Nasal and ocular allergy symptoms, quality of life, and breathing zone particulate exposure were assessed. Bedroom allergen dust samples were collected in the sleeping environment.
Reductions (>99.99%) in allergen-sized particulate (> or = 0.3 microm) in the breathing zone led to significant improvements in nocturnal nasal and ocular allergy symptoms (P < .001) and quality of life (P = .02) for the active vs placebo device. Significant nocturnal symptom reductions vs placebo occurred the second night of use and were maintained for the duration of treatment; these reductions improved sleep problems in particular (P = .02). Allergens were detected in 100% of bedrooms, of which 44% had levels that exceeded sensitizing thresholds.
The combination therapy of pillow encasement and localized air filtration provided effective nighttime allergen exposure reductions and clinical benefits without the use of adjunctive therapy.
夜间过敏原暴露是引发过敏和哮喘发病的主要原因。疾病管理指南建议使用环境控制措施来减少这些暴露，但由于大多数措施只能控制卧室环境中众多过敏原源中的 1 种，因此很难实现临床相关的减少。
确定一种新的局部夜间过敏原回避方法是否能提供有效的暴露减少和临床益处。
35 名患有常年性过敏性鼻结膜炎（对狗、猫或尘螨敏感）的成年人被随机分配接受 PureZone，这是一种涉及局部空气过滤和枕头套的联合治疗，或在交叉试验中接受安慰剂，该试验有两个为期 2 周的治疗期，中间间隔 1 周洗脱期。评估鼻和眼部过敏症状、生活质量和呼吸区颗粒物暴露情况。在睡眠环境中收集卧室过敏原灰尘样本。
呼吸区过敏原大小的颗粒物（≥0.3 微米）减少>99.99%，导致夜间鼻部和眼部过敏症状（P<.001）和生活质量（P=.02）显著改善，与安慰剂装置相比。与安慰剂相比，在使用第二天晚上就出现了显著的夜间症状减轻，并且在治疗期间得以维持；这些减轻尤其改善了睡眠问题（P=.02）。在所有卧室中都检测到过敏原，其中 44%的过敏原水平超过了致敏阈值。
枕头套和局部空气过滤的联合治疗提供了有效的夜间过敏原暴露减少和临床益处，而无需使用辅助治疗。
